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Introduction {#sec1}
============

DiGeorge/velo-cardio-facial/22q11 deletion syndrome (DGS, VCFS, 22q11 delS) is the most common deletion syndrome in humans ([@bib31]) and is characterized by severe cardiac and aortic arch defects, thymus dysplasia, cleft palate, and craniofacial abnormalities ([@bib18]). Despite its characteristic genetic lesion, the syndrome shows a remarkable variability in phenotypic severity. Newborn infants who lack the same 22q11 deletion interval can present with severe aortic arch and heart defects requiring surgery or, alternatively, have no detectable cardiovascular defects. Even monozygotic twins can exhibit this level of discordance, suggesting that the phenotypic variability cannot be explained on the basis of genetic differences alone ([@bib8]). As a consequence, chromatin modifiers are of great interest because they have the potential to integrate environmental effects and directly alter expression levels of key regulators of aortic arch and heart development.

Among the genes in the 1.5--3 Mb hemizygous deletion interval on chromosome 22q11 causing DGS, the *TBX1* gene is a major contributor to the characteristic clinical features seen in patients. The *TBX1* gene encodes a *T box* DNA-binding transcription factor, and mutations in one allele of the *TBX1* gene can lead to the same syndrome without 22q11 deletion ([@bib26]; [@bib33]; [@bib38]; [@bib47]; [@bib51]). Furthermore, heterozygous mutations of the *Tbx1* gene in mice model DGS ([@bib11]; [@bib20]; [@bib21]). We show here that a chromatin modifier, the monocytic leukemia zinc finger protein (MOZ/MYST3/KAT6A), is a critical regulator of the *Tbx1* gene in vivo.

MOZ, a member of the MYST family of histone acetyltransferases ([@bib28]; [@bib35]; [@bib40]), was first identified as a target of recurrent translocations causing a particularly aggressive form of acute myeloid leukemia ([@bib2]). The *Moz* gene is expressed widely at moderate levels ([@bib36]; [@bib42]), but mutation of the *Moz* gene has surprisingly specific effects. MOZ is required for the development of hematopoietic stem cells ([@bib12]; [@bib36]), thymus development ([@bib36]), histone 3 lysine 9 (H3K9) acetylation, and transcriptional activity at *Hox* gene loci and body segment identity specification ([@bib42]).

Through the use of *Moz* and *Tbx1* mutant mice, expression analysis, chromatin immunoprecipitation (ChIP), and pharmacological treatment, we report here a role of MOZ in cardiac, pharyngeal apparatus, and facial development. We show that MOZ is required for H3K9 acetylation (H3K9ac) and transcription at the *Tbx1* locus in vivo, and not essential for a range of other loci regulating cardiac development. Significantly, we demonstrate that *Moz* mutation leads to the spectrum of defects seen in DGS, that a *Tbx1* transgene rescues the heart defects in *Moz* mutant mice, that *Moz* exhibits synergistic genetic interaction with *Tbx1*, and that *Moz* haploinsufficiency synergizes with oversupply of retinoic acid (RA).

Results {#sec2}
=======

*Moz* Deficiency Leads to Anomalies Characteristic of DGS and *Tbx1* Deficiency {#sec2.1}
-------------------------------------------------------------------------------

Two *Moz* mutant alleles were used in this study: *Moz*^*Δ*^ and *Moz*^−^. The carboxy-terminal deletion allele, *Moz*^*Δ*^, does not produce detectable protein, as examined by immunoblotting ([@bib36]). *Moz*^*Δ/Δ*^ homozygous mice are born at a normal Mendelian ratio and die within the first hour after birth. In the *Moz*^−^ allele exons 3--7 were deleted ([@bib42]). *Moz*^−*/*−^ embryos die between embryonic day 14.5 (E14.5) and birth, depending on the genetic background. Homozygosity of either allele causes the absence of transplantable hematopoietic stem cells ([@bib36]; unpublished data), anterior homeotic transformation ([@bib42]), and the defects reported here. Based on the differences in time of death and in the severity of the defects between the two alleles, the *Moz*^−^ allele is the more severe loss-of-function allele, and it is inferred that the *Moz*^*Δ*^ allele must produce some residual, albeit not detectable and truncated, MOZ protein. *Moz*^*Δ/Δ*^ homozygotes were used to study the full spectrum of anatomical defects at birth, and *Moz*^−*/*−^ homozygotes were used for biochemical studies.

Newborn *Moz*^*Δ/Δ*^ mice (33 of 33) were of normal size. The morphology and histology of most organs were normal. However, all *Moz*^*Δ/Δ*^ mutant newborn pups had micrognathia ([Figures 1](#fig1){ref-type="fig"}A and 1B) and cleft palate ([Figures 1](#fig1){ref-type="fig"}C--1F; see [Figure S1](#app2){ref-type="sec"} available online; [Table 1](#tbl1){ref-type="table"}). In addition, we have previously reported the absence or hypoplasia of the thymus in 100% of *Moz*^*Δ/Δ*^ mutant newborn pups ([@bib36]).

Macroscopic examination, ink injection, and resin casting showed that *Moz*^*Δ/Δ*^ mutants most commonly exhibited an interrupted aortic arch between the left common carotid artery and the left subclavian artery, i.e., interrupted aortic arch type B (IAA-B) (74%; [Figures 1](#fig1){ref-type="fig"}G--1J; [Table 1](#tbl1){ref-type="table"}). In this condition, the ascending aorta is not connected to the descending aorta ([Figures 1](#fig1){ref-type="fig"}H and 1J). In 26% of *Moz*^*Δ/Δ*^ mutants, the pulmonary trunk was curved to the right side, forming an abnormal right aortic arch and a right descending aorta ([Figure S1](#app2){ref-type="sec"}). Other abnormalities observed included retropharyngeal/retrotracheal right subclavian artery (RSA), abnormal origin of the RSA, and incompletely remodeled great vessel walls, which appear dilated in diameter and thin walled ([Figure S1](#app2){ref-type="sec"}). The aortic arch defects in *Moz*^*Δ/Δ*^ newborn pups closely resembled anomalies observed in patients with DGS and reported in mice in an allelic series of *Tbx1* mutations ([Table 1](#tbl1){ref-type="table"}).

Ink injection into the inferior vena cava and resin casts of the heart cavities ([Figures 1](#fig1){ref-type="fig"}K--1M) showed that 95% of *Moz*^*Δ/Δ*^ mutant newborns lacked separation of the left and right side of the heart at the level of the ventricles (n = 19 *Moz*^*Δ/Δ*^, 16 *Moz*^*Δ/+*^, and 17 *Moz*^*+/+*^ newborn pups). Some *Moz*^*Δ/Δ*^ mutant newborns showed atrial septal defects in addition ([Table 1](#tbl1){ref-type="table"}). Serial histological sections showed overriding aorta and ventricular septal defects (VSDs) of varying severity affecting either large parts of the septum ([Figures 1](#fig1){ref-type="fig"}N and 1O) or the superior, membranous part of the ventricular septum ([Figure S1](#app2){ref-type="sec"}). Varying degrees of cardiac defects are also observed in approximately 80% of patients suffering from DGS ([Table 1](#tbl1){ref-type="table"}).

Overall, *Moz*^*Δ/Δ*^ mutant newborn mice exhibited the full spectrum of facial, palatal, thymic, aortic arch, and cardiac septal defects described in DGS and encompass defects observed in mice in a series of *Tbx1* mutant alleles ([Table 1](#tbl1){ref-type="table"}; [@bib3]; [@bib11]; [@bib13]; [@bib20]; [@bib21]; [@bib31]; [@bib39]; [@bib45]; [@bib47]; [@bib49]).

Embryonic Pathogenesis of the *Moz* Mutant Aortic Arch Defects {#sec2.2}
--------------------------------------------------------------

Examination of the developmental origin of the aortic arch defects uncovered a failure in fourth pharyngeal arch artery (PAA) development. Between E9.5 and E10.5 (4--5 weeks in human), the fourth PAAs develop. Between E10.5 and E12.5 (5--8 weeks in human), asymmetric remodeling of the PAAs begins and results in the formation of the aortic arch from the fourth PAA on the left side of the body, which then connects the ascending aorta to the descending aorta ([Figures 1](#fig1){ref-type="fig"}P--1R). Although the aorta/PAA system was normal in *Moz*^*Δ/Δ*^ embryos at E9.5 ([Figures 1](#fig1){ref-type="fig"}S and 1T; overview in [Figure S1](#app2){ref-type="sec"}), the fourth PAA had failed to develop on the left side in E10.5 *Moz*^*Δ/Δ*^ embryos ([Figures 1](#fig1){ref-type="fig"}U--1X), resulting in the failure to connect the ascending and descending aorta (interrupted aortic arch; [Figures 1](#fig1){ref-type="fig"}J and 1R). The fourth PAA on the right body side is reduced in diameter in *Moz*^*Δ/Δ*^ embryos ([Figure S1](#app2){ref-type="sec"}).

We conclude that the aortic arch anomalies observed in *Moz*^*Δ/Δ*^ mutant newborn arise from a failure of fourth PAA development between E9.5 and E10.5. Hypoplasia or aplasia of the fourth PAA at E10.5 has been described as the "hallmark of *Tbx1* haploinsufficiency" ([@bib27]).

*T box* Gene Expression Is Reduced in *Moz*-Deficient Embryos {#sec2.3}
-------------------------------------------------------------

Three findings suggested that the pathogenic mechanism of the *Moz* mutant phenotype involved the *Tbx1* gene: (1) the *Moz* loss-of-function defects were similar to the anomalies observed in patients with DGS; (2) the *Moz* loss-of-function defects encompassed those reported in mice within an allelic series of *Tbx1* mutation; and (3) based on our previous study of the role of MOZ in the regulation of *Hox* gene expression, we postulated that the expression of putative MOZ target gene(s) responsible for the velo-cardio-facial anomalies may only be reduced by approximately one-half. Because haploid mutation of the *TBX1* gene in humans can cause DGS ([@bib26]; [@bib33]; [@bib38]; [@bib47]; [@bib51]), we determined mRNA expression levels of the *Tbx1* gene in *Moz* mutant and control embryos. In addition, we determined expression of the immediate genomic neighbors of *Tbx1* ([Figure 2](#fig2){ref-type="fig"}A; *Gnb1l*, *Gp1bb*, *Sept5*) and another gene deleted in the larger 22q11 deletion interval, *Crkl*, because homozygous mutations in *Crkl* in mice cause DGS-like defects ([@bib10]). Furthermore, we examined genes encoding other transcription factors involved in heart development ([Figure 2](#fig2){ref-type="fig"}B; *Nkx2.5*, *Gata4*, *Tbx2*, *Tbx5*, *Tbx20*, *Pitx2*, *Foxa2*, *Foxc1*, *Foxc2*), along with other genes encoding T-box proteins for comparison (*Tbx3*, *Tbx4*) and three housekeeping genes (*Pgk1*, *Hsp90ab1*, *Gapdh*).

*Tbx1* was the only one of seven genes examined at E8.5 that showed significantly reduced mRNA levels in *Moz*^−*/*−^ mutant embryos as compared to wild-type littermate controls ([Figures 2](#fig2){ref-type="fig"}C and 2D), which corresponds to the timing requirement of *Tbx1* for fourth PAA formation ([@bib46]). One day later at E9.5, mRNA levels of *Tbx1* and *Tbx5* were reduced in *Moz*^−*/*−^ mutant embryos ([Figure 2](#fig2){ref-type="fig"}E). mRNA levels of other genes, including *Nkx2-5*, *Gata4*, and *Crkl*, were normal ([Figures 2](#fig2){ref-type="fig"}E--2H). Expression levels of *Tbx1* in E9.5 *Moz*^−*/*−^ mutant embryos were approximately 50% of wild-type levels. By E10.5, mRNA levels of *Tbx1*, *Tbx2*, and *Tbx5* were reduced in *Moz*^−*/*−^ mutant embryos ([Figure 2](#fig2){ref-type="fig"}I). Differences in *Tbx1* mRNA levels were also detectable at E11.5 as assessed by northern blot and densitometry (data not shown). Of interest, given the high frequency of PAA remodeling defects in *Moz* mutants, reduction of *Tbx1* to just 70% of the wild-type expression level is sufficient to result in fourth PAA patterning defects and hypoplasia ([@bib49]).

RNA/RNA in situ hybridization of E9.5 sections and whole-mount E10.5 embryos revealed that, whereas wild-type embryos exhibited the previously published expression patterns ([@bib5]; [@bib23]), expression of *Tbx1* was almost absent in some *Moz*^*Δ/Δ*^ mutant embryos ([Figures 3](#fig3){ref-type="fig"}A and 3B) or was reduced ([Figures 3](#fig3){ref-type="fig"}C--3F). Similarly, expression levels of *Tbx2* ([Figures 3](#fig3){ref-type="fig"}G and 3H) and *Tbx5* ([Figures 3](#fig3){ref-type="fig"}I and 3J), as well as *Tbx3* ([Figure S2](#app2){ref-type="sec"}), were reduced. Overall, the expression analysis suggests that of the cardiac development genes examined here, the first affected by the absence of MOZ is *Tbx1*, whereas effects on *Tbx5* and *Tbx2* are delayed by 24 and 48 hr, respectively.

*Moz* Mutant Embryos Lack H3K9ac at *T box* Gene Loci {#sec2.4}
-----------------------------------------------------

We have previously shown that MOZ is required for H3K9ac at *Hox* gene loci in E10.5 embryos ([@bib42]). High levels of H3K9ac are associated with the transcriptionally active state of gene loci ([@bib34]). In contrast, H3K9 trimethylation (H3K9me3) is associated with transcriptional repression, recruitment of silencing factors ([@bib1]; [@bib14]), and DNA methylation ([@bib7]).

We examined histone modification levels in vivo at *Tbx* gene loci ([Figure 4](#fig4){ref-type="fig"}A) in E10.5 *Moz*^−*/*−^ mutant and control embryos by ChIP-quantitative PCR (qPCR) ([Figure 4](#fig4){ref-type="fig"}). Histone modifications were unaffected by the *Moz* mutation at a total of six reference genes (*B2m*, *Pgk1*, *Rpl13a*, *Hsp90ab1*, *Alb*, *Hbb*; data not shown). We observed that the levels of H3K9ac were reduced in *Moz*^−*/*−^ mutant embryos at the *Tbx1* and *Tbx5* loci near the start site of transcription ([Figure 4](#fig4){ref-type="fig"}B), 0.7--1 kb upstream of the start site of the *Tbx1*, *Tbx2*, and *Tbx5* gene ([Figure 4](#fig4){ref-type="fig"}C) and in the *Tbx1* coding region ([Figure 4](#fig4){ref-type="fig"}D). In contrast to H3K9ac, presence or absence of MOZ had no effect on H3K14ac ([Figures 4](#fig4){ref-type="fig"}E--4G). The loss of H3K9ac was accompanied by a corresponding increase in the repressive H3K9 modification mark, H3K9me3 ([Figures 4](#fig4){ref-type="fig"}H and 4I). Our data reveal a requirement for MOZ for acetylation of H3K9 and transcriptional activity of the *Tbx1*, *Tbx2*, and *Tbx5* loci in vivo.

In HeLa cells, MOZ associates with ING5 and acetylated histone 3 as part of the MOZ-ING5 complex ([@bib6]). Because ChIP-quality antibodies to MOZ are not available, we examined binding of the MOZ complex protein ING5 to *Tbx* loci in lieu of MOZ ([Figures 4](#fig4){ref-type="fig"}J and 4K). ING5 associated with *Tbx1* and *Tbx5* in wild-type embryos showing that components of the MOZ complex occupy these loci. In contrast, ING5 occupancy of the *Tbx1* and the *Tbx5* locus was significantly reduced in embryos homozygous for the *Moz* null allele, *Moz*^−*/*−^ ([Figure 4](#fig4){ref-type="fig"}J), whereas ING5 occupancy at the *Tbx2* and *Tbx3* loci was not affected by MOZ ([Figure 4](#fig4){ref-type="fig"}K).

If the effects of MOZ on histone modification and expression of the *Tbx1* and *Tbx5* loci were indirect, one would expect to see all histone modification marks associated with gene activation, including H3K14ac, reduced in the *Moz* mutants. Our observation that *Moz* mutation reduces the binding of the MOZ complex protein ING5 to the *Tbx1* and *Tbx5* loci and H3K9ac, but not H3K14ac, suggests that MOZ acts directly on the *Tbx1* and *Tbx5* loci to acetylate H3K9 and regulates their expression.

Effects of MOZ on Regulators and Targets of TBX1 {#sec2.5}
------------------------------------------------

To examine the regulatory network of transcription factors that cooperate with TBX1 in heart development, we determined the effects of loss of *Moz* on a number of genes encoding transcription factors that were reported to induce *Tbx1* gene transcription, i.e., FOXA2, FOXC1, and FOXC2 ([Figure 2](#fig2){ref-type="fig"}B; [@bib48]) and a known target gene of TBX1, *Pitx2* ([Figure 2](#fig2){ref-type="fig"}B; [@bib25]). At E8.5, none of the *forkhead* genes, *Foxa2*, *Foxc1*, or *Foxc2*, exhibited a reduction in mRNA levels in the *Moz*^−*/*−^ mutant embryos. In fact, *Foxc1* mRNA levels were elevated in the *Moz*^−*/*−^ mutant embryos as compared to controls ([Figure 5](#fig5){ref-type="fig"}A). At E9.5 and E10.5, *Foxa2* mRNA levels were not different between *Moz*^−*/*−^ mutant embryos and controls, whereas *Foxc1* and *Foxc2* mRNA levels were now reduced in the *Moz*^−*/*−^ mutant embryos ([Figures 5](#fig5){ref-type="fig"}B and 5C). Expression of *Pitx2* requires TBX1 as a transcriptional activator ([@bib25]). As expected in a TBX1-deficient state, *Pitx2* mRNA levels were reduced in E9.5 and E10.5 *Moz*^−*/*−^ mutant embryos as compared to control ([Figure 5](#fig5){ref-type="fig"}D). The *Chd7* gene encodes, like *Moz*, a chromatin modifier, namely the chromodomain helicase DNA-binding protein CHD7 and interacts genetically with the *Tbx1* locus ([@bib27]). In contrast to the TBX1 target gene *Pitx2*, *Chd7* gene expression was unaffected by the mutation of *Moz* ([Figure 5](#fig5){ref-type="fig"}E). Of the three forkhead proteins, ChIP-quality antibodies could only be obtained for FOXA2. The *Tbx1* locus is regulated by forkhead transcription factors through binding to a number of mutually redundant transcription factor binding sites ([@bib50]). We examined a consensus forkhead binding site, which is more than 14 kb upstream of exon 1 of the *Tbx1* locus and highly conserved between humans and mice ([@bib48]) (for details see [Supplemental Experimental Procedures](#app2){ref-type="sec"}). The site was bound by FOXA2 protein, and occupancy was increased in the *Moz*^−*/*−^ mutant embryos, as compared to wild-type controls ([Figure 5](#fig5){ref-type="fig"}F), suggesting that the reduced *Tbx1* mRNA (or protein) levels induced recruitment of the transcriptional activator to the *Tbx1* locus via a feedback mechanism. However, despite this increased recruitment of FOXA2 to the *Tbx1* locus, *Tbx1* gene transcription was approximately half of normal in the absence of MOZ ([Figure 2](#fig2){ref-type="fig"}), indicating that MOZ is specifically required for normal *Tbx1* transcription, and the forkhead transcription factors are unable to drive normal levels of transcription without MOZ. The reduction in *Foxc1* and *Foxc2* mRNA levels at E9.5 and E10.5 conflicted with unchanged or increased mRNA levels at E8.5, suggesting that these were indirect consequences of loss of MOZ. Nevertheless, we examined if MOZ affected the occupancy of the transcription start site of the *Foxc1* and *Foxc2* gene by ING5, the member of the MOZ complex. ING5 occupancy of the *Foxc1* locus was low and not significantly different in *Moz*^−*/*−^ mutant and control embryos ([Figure 5](#fig5){ref-type="fig"}G), and ING5 did not bind to the *Foxc2* locus (data not shown), indicating that the *Foxc1 and Foxc2* genes are not direct targets of MOZ. Occupancy of the *Pitx2* locus by ING5 was not affected by the absence or presence of MOZ ([Figure 5](#fig5){ref-type="fig"}G), suggesting that the reduction in *Pitx2* transcriptional activity was an indirect effect of MOZ, presumably via reduction of TBX1 levels.

Genetic Interaction between the *Moz* and the *Tbx1* Locus {#sec2.6}
----------------------------------------------------------

If deficiencies in MOZ contributed to the phenotypic variability of velo-cardio-facial defects via a failure of activation of *Tbx1* gene expression, a genetic interaction between the *Moz* and the *Tbx1* gene would be expected. Therefore, we examined wild-type, *Tbx1*^*lacZ/+*^, and *Moz*^*+/*−^ single- and double-heterozygous mice for viability and anomalies. Among 148 offspring of *Tbx1*^*lacZ/+*^ by *Moz*^*+/*−^ matings were only 8 *Tbx1*^*lacZ/+*^*Moz*^*+/*−^ double heterozygous at weaning ([Figure 6](#fig6){ref-type="fig"}A), indicating that 80% of *Tbx1*^*lacZ/+*^*Moz*^*+/*−^ double heterozygotes had died. At E17.5--E18.5 a large proportion of *Tbx1*^*lacZ/+*^*Moz*^*+/*−^ double heterozygous exhibited DGS-like anomalies, significantly larger than the frequency calculated for mere additive effects of *Moz* and *Tbx1* heterozygosity ([Figure 6](#fig6){ref-type="fig"}B). A total of 120 E17.5--E18.5 fetuses were examined for defects by macroscopic dissection ([Figure 6](#fig6){ref-type="fig"}C) and 79 by serial sectioning and examination of the heart ([Figure 6](#fig6){ref-type="fig"}D). Wild-type littermate controls showed no anomalies. Among *Moz*^*+/*−^ single heterozygotes we observed RSA, great vessel wall remodeling, and craniofacial defects, as well as minor VSDs ([Figures 6](#fig6){ref-type="fig"}B--6D). Among *Tbx1*^*lacZ/+*^ single heterozygotes we saw aortic arch, RSA, and palate defects ([Figures 6](#fig6){ref-type="fig"}B--6D). DGS-like anomalies were more frequent and more severe in the *Tbx1*^*lacZ/+*^*Moz*^*+/*−^ double heterozygotes ([Figure 6](#fig6){ref-type="fig"}B) and included cleft palate, thymus hypoplasia, IAA-B, and abnormal RSAs ([Figure 6](#fig6){ref-type="fig"}C) and large VSDs ([Figure 6](#fig6){ref-type="fig"}D). The more than additive rise in incidence of DGS-like anomalies and the increase in severity in the double heterozygotes demonstrate synergistic epistasis between *Moz* and *Tbx1* mutation.

Rescue of the *Moz*^*Δ/Δ*^ Heart Phenotype by a *Tbx1* Transgene {#sec2.7}
----------------------------------------------------------------

Because we hypothesized that the reduction in *Tbx1* transcriptional activity in the *Moz* mutants is a mechanistic contributor to the DGS-like defects in the *Moz* mutant mice, we expected that *Tbx1* overexpression might rescue the DGS-like defects of *Moz* mutant mice at least partially. We generated *Tbx1 BAC* transgenic mice with one exogenous copy of the *Tbx1* gene, resulting in an elevation of *Tbx1* mRNA levels to 128% ± 7% (SEM) of wild-type on the *Moz* wild-type background and a rescue of *Tbx1* mRNA levels to 88% ± 8% of wild-type on the *Moz*^*Δ/Δ*^ background (n = 10 E9.5 embryos per genotype). Although one additional copy of *Tbx1* was unable to rescue the aortic arch and palate defects, one copy of the *Tbx1*-containing *BAC* rescued the cardiac septal defects, in all three *Moz*^*Δ/Δ*^ *Tbx1-*transgenic animals examined ([Figures 6](#fig6){ref-type="fig"}E, 6F, and [S3](#app2){ref-type="sec"}). Examination of serial sections of *Moz*^*Δ/Δ*^ mutant hearts revealed cardiac septation defects in all four *Moz*^*Δ/Δ*^ hearts in this experiment (three with VSDs and one with an aortopulmonary septal defect), as expected based on the septal defects observed in 18 of 19 *Moz*^*Δ/Δ*^ mutant hearts examined in experiments described above (95% penetrance, [Figure 1](#fig1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). In contrast, all three *Moz*^*Δ/Δ*^ *Tbx1-*transgenic hearts had intact cardiac and aortopulmonary septa. The rescue indicates that the deficiency in *Tbx1* gene expression underlies the cardiac septal defects observed in the *Moz* homozygous mutant mice.

RA Increases Penetrance of DGS-like Defects in *Moz*^*+/*−^ Mice {#sec2.8}
----------------------------------------------------------------

We hypothesized that *Moz* haploinsufficiency might render an individual sensitive to environmental influence. To test this hypothesis, we investigated if dietary supplementation with RA affected the incidence of DGS-like anomalies in *Moz* heterozygotes because oversupply with vitamin A or RA has been reported to cause DGS-like anomalies ([@bib15]). Of 30 mice heterozygous for the *Moz*^−^ null allele, three exhibited small VSDs ([Figure 6](#fig6){ref-type="fig"}D). In contrast, none of the mice heterozygous for the carboxy-terminal deletion allele *Moz*^*Δ*^ had DGS-like anomalies ([Figure 7](#fig7){ref-type="fig"}A, Untreated). We used the *Moz*^*Δ*^ allele because it appeared to provide just enough MOZ activity in *Moz*^*Δ/+*^ heterozygotes to prevent DGS-like defects to occur spontaneously. We examined the effects of RA during a critical phase of PAA and outflow tract development, i.e., from E7.25 to E9.25. Dietary RA at E7.25 had no effects on aortic arch morphology in E17.5--E18.5 fetuses. However, dietary RA at E8.25 and E9.5 caused DGS-like anomalies in 42% and 25% of *Moz*^*Δ/+*^ heterozygotes, respectively ([Figure 7](#fig7){ref-type="fig"}A). In contrast, only 11% of the RA-treated wild-type controls at E8.5 and none of the controls at E9.5 showed DGS-like symptoms. The anomalies observed in the RA-treated *Moz*^*Δ/+*^ heterozygotes included cleft secondary palate, hypoplasia of the thymus, abnormal RSA, transposition of the great arteries, and IAA-B ([Figure 7](#fig7){ref-type="fig"}B).

Collectively, our findings show that homozygous mutation of the *Moz* gene or *Moz* heterozygous mutation combined with either *Tbx1* haploinsufficiency or oversupply of RA during pregnancy causes anomalies that resemble DGS with high penetrance (40%--60% in haploid state and 100% in the homozygous state) and include severe defects, i.e., IAA-B and VSD. Importantly, one copy of a *Tbx1* transgene rescued the cardiac septal defects in *Moz* homozygous mutants.

Discussion {#sec3}
==========

We have shown that(1)MOZ has highly specific functions in the development of the palate, facial structures, thymus, and the cardiovascular system, and lack of MOZ produces defects closely resembling DGS.(2)MOZ is required for normal levels of *Tbx1* mRNA and(3)normal levels of H3K9ac at the *Tbx1* locus.(4)The MOZ complex protein ING5 binds to the *Tbx1* locus in the presence of MOZ.(5)Homozygous mutation of *Moz* alone or heterozygous mutation of *Moz* in combination with either(6)*Tbx1* haploinsufficiency or(7)oversupply of RA in the diet causes DGS-like anomalies, including IAA-B, thymus aplasia, or hypoplasia, cleft palate, and VSD.(8)One copy of a *Tbx1* transgene rescues the cardiac septal defects seen in *Moz* mutant mice.

The structures affected in the *Moz* mutant embryos are derived from *Tbx1*-positive aspects of the pharyngeal arches (aortic arch, thymus, palate) and the *Tbx1* and *Pitx2*-positive derivatives of the second heart field. One-third of newborn *Tbx1* heterozygous display minor great vessel remodeling defects, but overt IAA-B occurs at a low frequency ([@bib19]). However, the combination of *Moz* and *Tbx1* haploinsufficiency generates the severe defects (IAA-B and large VSDs) as well as other DGS-like defects at a higher frequency than would be expected from additive effects of the two haploinsufficiencies, showing a synergistic effect of haploid loss of *Moz* and *Tbx1*. Unlike other genes reported to exhibit genetic interaction with the *Tbx1* locus in causing DGS-like defects *(Fgf8*, *Crkl*, *Gbx2*, *Pitx2*, *Chrd*), *Moz* and another chromatin modifier, *Chd7*, showed DGS-like defects in the single-heterozygote state (data reported here and [@bib27] for *Chd7*).

Our study does not exclude the possible involvement of other MOZ target genes. Indeed, we show here that apart from *Tbx1*, the *Tbx5* locus is also regulated by MOZ, albeit later than *Tbx1*. In addition, we have previously shown that MOZ is required for H3K9ac and expression of *Hox* loci and is critical for body segment identity specification ([@bib42]). RA treatment of *Moz* mutant embryos rescued *Hox* gene expression, H3K9ac, and segment identity. In contrast, RA treatment enhanced the DGS-like defects showing that the upregulation of *Hox* gene expression does not ameliorate the DGS-like defects, rendering it unlikely that the DGS-like defects were mediated by reduced *Hox* gene expression in the MOZ-deficient state. The fact that one additional copy of *Tbx1* rescues the cardiac septal defects observed in *Moz* mutant mice demonstrates that MOZ acts via the *Tbx1* gene in cardiac septal development. The observation that one additional copy of *Tbx1* does not rescue the aortic arch and palate defects in *Moz* mutant mice suggests that one additional copy of *Tbx1* may not be sufficient but may also indicate that other genes are involved in the development of these structures in addition to *Tbx1*.

Discordance of anomalies is observed between monozygotic twins with DGS ([@bib8]) and C57BL/6 inbred *Tbx1*^*lacZ/+*^ mice (our own observation), showing that genetic factors alone are an inadequate explanation for phenotypic variation. The effects of environmental factors mediated by chromatin modifications must therefore play an important role in determining the phenotypic outcome in DGS. Although other chromatin modifiers are known to be required for heart development ([@bib4]; [@bib9]; [@bib17]; [@bib22]; [@bib24]; [@bib27]; [@bib30]; [@bib32]; [@bib44]), the effects of loss of these on chromatin at the *Tbx1* locus were either not examined, or no effect was observed ([@bib9]; [@bib17]; [@bib32]). In contrast, our results show effects of a chromatin modifier, MOZ, on the transcriptional activity through discrete changes of the chromatin at the *Tbx1* locus.

Environmental factors known to affect aortic arch and heart development include, among others, vitamin A oversupply and pharmacological overexposure to RA, which can mimic the palate, VSD, thymus, and aortic arch defects seen in DGS ([@bib15]). RA is known to suppress *Tbx1* gene expression ([@bib29]), and the phenotypic outcome in models of DGS appears to be exquisitely sensitive to gene dosage and time course of *Tbx1* gene expression ([@bib16]; [@bib46]; [@bib49]). Indeed, mice heterozygous for a hypomorphic *Moz* allele, which do not display DGS-like defects, responded sensitively to oversupply of RA and develop defects in aortic arch, thymus, and palate development, in the time frame consistent with sensitivity to *Tbx1* gene expression levels.

In conclusion, we postulate that MOZ, via H3K9ac, drives transcriptional activity of the *Tbx1* locus and is essential for aortic arch, heart, thymus, and palate development. The robust development of these structures depends on the presence of two copies of the *Moz* gene. Importantly, this system is susceptible to perturbations both at the genetic and chromatin level and exquisitely sensitive to environmental insults at key developmental stages.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

All animal experiments were approved by the Walter and Eliza Hall Institute Animal Ethics Committee and conducted in accordance with the Australian code of practice for the care and use of animals for scientific purposes. Mice heterozygous for a carboxy-terminal deletion of MOZ, *Moz*^*Δ/+*^ ([@bib36]), or carrying a *Moz* null allele, *Moz*^*+/*−^ ([@bib42]), on an *FVB/BalbC* hybrid background were used as indicated in the text and figure legends. *Tbx1* BAC transgenic mice were generated by pronuclear microinjection of *BAC RP23-35B9*, which contains the *Tbx1* gene at its center. *Tbx1 BAC* transgenic line *T1-33*, which contained one copy of the *Tbx1* transgene, was used. Apart from the *Tbx1* gene, the BAC contains *Sept5*, which is not expressed at the relevant developmental stage, as well as *Gp1bb* and part of *Gnbl1*. The expression of neither of these two genes is affected by the presence or absence of *Moz* ([Figure 2](#fig2){ref-type="fig"}F). Although the DGS-like defects were highly penetrant in *Moz*^−*/*−^ homozygous mice regardless of the genetic background, *Tbx1*^*lacZ/+*^([@bib20]) and *Moz*^*+/*−^ mice, both on a C57BL/6 background, were used for the genetic interaction studies because the penetrance of defects in heterozygotes of both strains was largely reduced on an outbred background. Noon following the morning observation of a vaginal mating plug was termed E0.5. Embryos and pups were collected at the developmental stages indicated in the text and figure legends. Palate, thymus, and aortic arch defects were scored during dissection prior to genotyping. Extraembryonic membranes or tails were used for genotyping by three-way PCR as described previously ([@bib20]; [@bib36]; [@bib42]). Oral supplementation with all-*trans* RA (Sigma-Aldrich; R2625) was performed as described previously ([@bib42]) at the developmental stages indicated in the figures.

Expression Analysis {#sec4.2}
-------------------

Whole-mount and radioactive in situ hybridization, total RNA isolation, northern blot analysis, and densitometry were conducted using standard techniques as previously described ([@bib37]; [@bib41]). cRNA and cDNA probes are listed in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}. qPCR was performed using a Roche LightCycler 480 and SYBR Green based detection. Details on primers are given in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

ChIP {#sec4.3}
----

ChIP followed by qPCR was carried out as described previously ([@bib42], [@bib43]) using primers described in [Supplemental Experimental Procedures](#app2){ref-type="sec"}. Antibodies used for ChIP, immunoblotting, and immunofluorescence were directed against ING5 (Abnova; H00084289-B01), FOXA2 (HNF-3b \[M-20\]: sc-6554; Santa Cruz Biotechnology), H3K9ac (Millipore; Upstate 07-352), H3K9me3 (Abcam; ab8898), and H3K14ac (Millipore; Upstate 07-353). The histone antibodies detect the modified forms preferentially over the other forms. Anti-IgG was used as a control in ChIP.

Statistics {#sec4.4}
----------

Data were analyzed using Intercooled Stata 10 software. RT-qPCR and ChIP-qPCR data are presented as standardized mean ± SEM of cDNA and gDNA concentration normalized for the housekeeping genes *Hsp90ab1*, *Pgk1*, and *Gapdh* for RT-qPCR and for either *β-2-microglobulin* and *Hsp90b* for transcriptionally active loci or *albumin* and *hemoglobin β* for transcriptionally inactive loci in the ChIP-qPCR experiments. Data were analyzed by one or two-factorial ANOVA with a number of intact *Moz* alleles with or without genomic locus as independent factors, followed by Bonferroni\'s post hoc test. Frequencies of genotypes at weaning and frequencies of DGS-like anomalies at E17.5--E18.5 in RA treatment experiments, genetic interaction, and rescue studies were examined by Pearson\'s chi-square test.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S3 and Supplemental Experimental Procedures
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![Craniofacial, Palate, Aortic Arch, and Heart Abnormalities in *Moz*^*Δ/Δ*^ Mutant Pups\
*Moz*^*+/+*^ (A, C, E, G, I, K, N, S, U, and W) and *Moz*^*Δ/Δ*^ (B, D, F, H, J, L, M, O, T, V, and X) newborn mouse pups (A--F), E18.5 pups (G--O), E9.5 (S and T), and E10.5 (U--X) embryos. Lateral view of the head (A and B), ventral view of the palate (C and D), and of the bone structure of the palate (E and F). Note the shortened face and mandible of the mutant (A and B), the lack of midline fusion of the secondary palate (arrow in D and F). Asterisks in (F) indicate location where the maxillary shelf and the palatine shelf should have fused. Aortic arch and other great vessels, ventral view, ink injected (G and H), and traced (I and J). Note the absence of the aortic arch between the LCCA and the LSA, i.e., an IAA-B (arrow in H and J) and the connection of the pulmonary trunk with the descending aorta (H and J). Resin cast of heart and large blood vessels (K--M) injected with red (left ventricle) and blue (right ventricle), H&E sections of hearts, ventral view (N and O). Note the complete filling of both sides of the *Moz*^*Δ/Δ*^ hearts by injection from either the right (L) or left (M) ventricle, the ventricular septum defect (arrow in O), and overriding aorta (asterisk in O). Schematic drawing of aortic arch development from E11.5 to E18.5 (P and Q) and abnormal vessels in E18.5 *Moz*^*Δ/Δ*^ mutants (R). Ink-injected aorta-pharyngeal complex at E9.5 (S and T) and E10.5 (U and V). Resin cast of the aorta-pharyngeal complex at E10.5 (W and X). The connection between the ascending and descending aspects of the aorta is derived from the left fourth pharyngeal artery (red in P and Q), missing in *Moz*^*Δ/Δ*^ (arrow, R). The left fourth pharyngeal artery is not yet developed at E9.5 in either *Moz*^*+/+*^ or *Moz*^*Δ/Δ*^ (S and T). Note, however, the presence of a fourth PAA in *Moz*^*+/+*^ E10.5 embryos (U and W), which is absent in *Moz*^*Δ/Δ*^ E10.5 embryos (4′ in V and X). 1b, mandibular portion of the first pharyngeal arch; 2, second pharyngeal arch; 3, 4, 6, third, fourth, and sixth PAA; arrowhead in (F), presphenoid bone, only visible through cleft palate; Ao, aorta; As, alisphenoid; Bs, basisphenoid; dAo, dorsal aorta; Ca, caudal; DA, ductus arteriosus; He, heart; LA, left atrium; LCCA, left common carotid artery; LSA, left subclavian artery; LPA, left pulmonary artery; LV, left ventricle; M, maxillary shelf; Mx, maxilla; OV, otic vesicle; P, palatine shelf; P2, secondary palate; Pa, pulmonary artery; Pm, premaxilla; PP, primary palate; PT, pulmonary trunk; RA, right atrium; RCCA, right common carotid artery; Ro, rostral; RSA, right subclavian artery; RV, right ventricle; SA, subclavian artery; vAo, ventral aorta; VS, ventricular septum. Z, zygomatic process. Scale bar, 5 mm (A and B), 2 mm (C and D), 1.5 mm (E and F), 940 μm (G and H), 2.3 mm (K), 1.5 mm (L), 1.2 mm (M), 550 μm (N and O), 1150 μm (S and T), 290 μm (U and V), and 230 μm (W and X). n = 33 *Moz*^*Δ/Δ*^, 45 *Moz*^*Δ/+*^, and 35 *Moz*^*+/+*^ newborn pups (A--F), n = 19 *Moz*^*Δ/Δ*^,13 *Moz*^*Δ/+*^, and 15 *Moz*^*+/+*^ newborn pups (G--J), n = 19 *Moz*^*Δ/Δ*^, 16 *Moz*^*Δ/+*^, and 17 *Moz*^*+/+*^ newborn pups (K--O). n = 12 *Moz*^*Δ/Δ*^, 14 *Moz*^*Δ/+*^, and 9 *Moz*^*+/+*^ E9.5 embryos (S and T), n = 4 *Moz*^*Δ/Δ*^, 20 *Moz*^*Δ/+*^, and 13 *Moz*^*+/+*^ control E10.5 embryos (U--X). See also [Figure S1](#app2){ref-type="sec"}.](gr1){#fig1}

![mRNA Expression Levels of Genes Regulating Heart Development and Genes within the 22q11 Deletion Interval\
(A) Schematic drawing of the genomic context of the *Tbx1* gene and genes flanking the locus on chromosome 16 in the mouse, a region syntenic with the 22q11 deletion interval in human.\
(B) Schematic representation of major regulators of transcription during heart development.\
(C--I) mRNA expression levels as assessed by RT-qPCR and normalized to housekeeping genes in *Moz*^*+/+*^ and *Moz*^−*/*−^ embryos at E8.5 (C and D), E9.5 (E--H), and E10.5 (I); mRNAs encoded by genes as indicated in the graphs. ^∗^p \< 0.05 and ^∗∗^p \< 0.01. Exact p values are given below. Significantly lower in *Moz*^−*/*−^ embryos were mRNAs encoded by *Tbx1* at E8.5 (C, p = 0.029), at E9.5 (E, p = 0.001), and E10.5 (I, p = 0.039); *Tbx5* at E9.5 (E, p = 0.011) and E10.5 (I, p = 0.006) and *Tbx2* at E10.5 (I, p = 0.014). Not significantly changed were the mRNA expression levels of housekeeping genes (D and H), other genes in the 22q11 deletion interval (F), and major regulators of heart development, *Gata4* and *Nkx2-5* (G). Data are presented and were analyzed as described in the [Experimental Procedures](#sec4){ref-type="sec"}. Data were derived from 36 embryos, n = 6 *Moz*^*+/+*^ and 6 *Moz*^−*/*−^ per gene at each developmental stage.](gr2){#fig2}

![Reduced Expression of *Tbx* Genes in *Moz*^*Δ/Δ*^ Embryos Detected by In Situ Hybridization\
*Moz*^*+/+*^ (A, C, E, G, and I) and *Moz*^*Δ/Δ*^ (B, D, F, H, and J) embryos, whole mount at E10.5 (A--D and G--J), and sections at E9.5 (E and F). Expression of *Tbx1* (A--F), *Tbx2* (G and H), and *Tbx5* (I and J). Note the substantial reduction (B) or more moderate reduction (D and F) in *Tbx1* mRNA signal in the *Moz*^*Δ/Δ*^ embryos (dark purple in whole mount), reduced *Tbx1* mRNA signal in the mesodermal core of the pharyngeal arches (black-silver grains, arrows E and F), and in the pharyngeal endoderm (asterisks, E and F) in the *Moz*^*Δ/Δ*^ embryos on sections. The region of the fourth pharyngeal arch is indicated (arrows, C and D). Note the reduction in *Tbx2* (G and H) and *Tbx5* mRNA signals (I and J, arrowhead indicates *Tbx5* expression maintained in the inflow tract at E10.5). 1a and 1b, maxillary and mandibular, respectively, aspect of the first pharyngeal arch; 2, 3, 4, second, third, and fourth pharyngeal arch; 4′, region where the fourth pharyngeal arch should be present in the *Moz*^*Δ/Δ*^; FL, forelimb bud; He; Heart; OV, otic vesicle. Scale bar, 190 μm (A and B), 390 μm (C and D), 142 μm (E and F), 350 μm (G and H), and 530 μm (I and J). Data were derived from 42 embryos, n = 6 *Moz*^*+/+*^ and 6 *Moz*^*Δ/Δ*^ per gene at E10.5 and 3 *Moz*^*+/+*^ and 3 *Moz*^*Δ/Δ*^ at E9.5. See also [Figure S2](#app2){ref-type="sec"}.](gr3){#fig3}

![H3K9ac and MOZ Complex Protein ING5 Occupancy Is Reduced at the *Tbx1* and *Tbx5* Gene Loci in the Absence of MOZ\
(A) Schematic drawing of the genomic loci assayed for histone modifications and ING5 occupancy by ChIP. "Tbx1_1, Tbx1_2, Tbx2_1 etc." denote sequences amplified in (B)--(K). H3K9ac (B--D), H3K14ac (E--G), H3K9me3 (H and I), and ING5 (J and K) were assessed by ChIP-qPCR of *Moz*^−*/*−^ and *Moz*^*+/+*^ E10.5 embryos for sequences −0.7 to −1.0 kb upstream of the TSS (B, E, H, and J; tiles_1), in proximity of the transcription start site (TSS; C, F, H, J, and K; tiles_2) and in the coding region (D and G). Note the reduction in H3K9ac in *Moz*^−*/*−^ mutants −0.7 to −1 kb upstream of the TSS of *Tbx1*, *Tbx2*, and *Tbx5* (B; p \< 0.0005, p = 0.003, and p = 0.003, respectively), near the TSS of *Tbx1* and *Tbx5* (C; p = 0.032 and p = 0.002, respectively), and in the *Tbx1* coding region (D; p = 0.0151), but no reduction in H3K14ac (E--G) and an increase in H3K9me3 (H and I; p = 0.0071). Notice the reduction in binding of the MOZ complex protein ING5 to *Tbx1* and *Tbx5* in *Moz*^−*/*−^ mutants (J; p = 0.001 and p \< 0.0005, respectively), but not *Tbx2* and *Tbx3* (K). For the effects of *Moz* mutation, p values \<0.05, \<0.01, and \<0.001 are indicated by one, two, and three asterisks, respectively. Data are presented and were analyzed as described in the [Experimental Procedures](#sec4){ref-type="sec"}. Data are derived from a total of 39 embryos, n = 6 *Moz*^*+/+*^ and 6 *Moz*^−*/*−^ per ChIP antibody (B--G), 3 *Moz*^*+/+*^ and 3 *Moz*^−*/*−^ (H, I, and K), and 4 *Moz*^*+/+*^ and 5 *Moz*^−*/*−^ (J).](gr4){#fig4}

![Expression of Genes Encoding Regulators of the *Tbx1* Gene, Genes Regulated by TBX1 Protein, and Genes Showing Genetic Interaction with the *Tbx1* Locus\
mRNA levels of genes as indicated assessed by RT-qPCR (A--E) and occupancy of gene loci as indicated by FOXA2 (F) and by the MOZ complex protein ING5 (G). Expression of the genes encoding the forkhead protein FOXA2 (A--C) reported to upregulate *Tbx1* gene expression, as well as the *Chd7* gene (E), reported to interact genetically with the *Tbx1* locus, is unaffected by *Moz* mutation at E8.5 (A), E9.5 (B and E), and E10.5 (C). *Tbx1* locus occupancy assessed by ChIP-qPCR by FOXA2 is increased in E9.5 *Moz*^−*/*−^ mutants (F; p = 0.015), albeit without being able to induce normal *Tbx1* expression levels in the absence of MOZ ([Figure 2](#fig2){ref-type="fig"}). Expression of *Foxc1* is increased at E8.5 (A, p = 0.04), and expression of *Foxc1* and *Foxc2* is decreased at E9.5 (B, p = 0.008 and p = 0.001, respectively) and E10.5 (C, p = 0.034 and p = 0.011, respectively) in *Moz*^−*/*−^ mutants without changes in occupancy of *Foxc1* locus by ING5 (G; p = 0.251) and without occupancy of the *Foxc2* locus by ING5 (data not shown). The expression of the *Pitx2* gene, a target gene of TBX1, is decreased at E9.5 and E10.5 in *Moz*^−*/*−^ mutants (D, p = 0.023) without changes in ING5 occupancy of the *Pitx2* locus (G). For the effects of *Moz* mutation, p values \<0.05 and \<0.01 are indicated by one and two asterisks, respectively. Data are presented and were analyzed as described in the [Experimental Procedures](#sec4){ref-type="sec"}. Data were derived from 48 embryos, n = 6 *Moz*^*+/+*^ and 6 *Moz*^*Δ/Δ*^ per developmental stage (A--E) and 3 *Moz*^*+/+*^ and 3 *Moz*^−*/*−^ (F and G).](gr5){#fig5}

![Genetic Synergy between *Moz* and *Tbx1* Haploinsufficiency and Rescue of *Moz* Mutant Heart Defects by a *Tbx1* Transgene\
(A) Survival of wild-type, *Moz*^*+/*−^ and *Tbx1*^*+/*−^ single-heterozygous, and *Moz*^*+/*−^*Tbx1*^*+/*−^ double-heterozygous mice to weaning. Note that 80% of *Moz*^*+/*−^*Tbx1*^*+/*−^ double-heterozygous mice are not viable.\
(B) Incidence of DGS-like anomalies observed in *Moz*^*+/*−^*Tbx1*^*+/*−^ double- and single-heterozygous mice at E17.5--E18.5.\
(C and D) Details of DGS-like anomalies in locations other than the heart (C) and in the heart (D) observed in the *Moz*^*+/*−^*Tbx1*^*+/*−^ double and single heterozygotes.\
(E and F) E18.5 offspring in three litters of *Moz*^*Δ/+*^*Tbx1-Tg* by *Moz*^*Δ/+*^ matings. (E) Overview and high-resolution images of VSDs in three *Moz*^*Δ/Δ*^ animals (arrows, as in [Figure 1](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}) and the rescue of the septal defects by one copy of the *Tbx1*-containing *BAC RP23-35B9* in three *Moz*^*Δ/Δ*^*Tbx1-Tg* animals (serial images in [Figure S3](#app2){ref-type="sec"}). (F) Summary of all 25 offspring. The septal defects observed in the four *Moz*^*Δ/Δ*^ were three VSDs and one aortopulmonary septal defect. Data are presented and analyzed as described in the [Experimental Procedures](#sec4){ref-type="sec"}. AbRSA, abnormal right subclavian artery including retrotracheal and abnormal origin; GVRD, great vessel wall remodeling defects, i.e., dilated in diameter and thin walled; LA, left atrium; LV, left ventricle; IAA-B, interrupted aortic arch type B; RA, right atrium; RV, right ventricle; VS, ventricular septum; VSD, ventricular septal defect. Scale bar, 445 μm in the left two panels of (E) and 185 μm in all other panels of (E).](gr6){#fig6}

![Sensitization to RA by Loss of One Copy of *Moz*\
(A) Effects of RA treatment at E7.25--E9.25 on *Moz*^*+/+*^, *Moz*^*Δ/+*^, and *Moz*^*Δ/Δ*^ E17.5--E18.5 pups on the incidence of DGS-like anomalies. Note the induction of DGS-like anomalies in heterozygotes treated with RA at E8.25 and E9.25.\
(B) Details of anomalies observed in the RA-treated *Moz*^*Δ/+*^ heterozygous animals. Data are presented and analyzed as described in the [Experimental Procedures](#sec4){ref-type="sec"}. Abnormal RSA, abnormal right subclavian artery including retrotracheal and abnormal origin; IAA type B, interrupted aortic arch type B; TGA, transposition of the great arteries.](gr7){#fig7}

###### 

Incidence of Specific Anomalies Observed in *Moz*^*Δ/Δ*^ Mutant Neonatal Mice Compared to Incidence Reported in Patients with DGS and *Tbx1* Mouse Mutants

  Finding                            *Moz*^*Δ/Δ*^ Mouse Neonates[a](#tblfn1){ref-type="table-fn"}   Patients with DGS (%)[b](#tblfn2){ref-type="table-fn"}   Mouse Neonates within a Series of *Tbx1* Mutant Alleles (%)[c](#tblfn3){ref-type="table-fn"}                                                     
  ---------------------------------- -------------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------------------------------------------------------- --------- ----- ----- ----- ----- ----- ---- ---- ----
  **Any major finding**              33/33                                                          100                                                      100                                                                                            --        100   100   100   100   100   --   --   --
  **Palatal anomalies**              33/33                                                          100                                                      16                                                                                             69--100   100   --    --    --    --    --   0    --
  Cleft bony palate                  33/33                                                          100                                                      --                                                                                             11        100   --    --    --    --    --   0    --
  **Absent or hypoplastic thymus**   33/33                                                          100                                                      28                                                                                             --        100   √     √     100   100   41   √    29
  **Skeletal**                       33/33                                                          100                                                      9                                                                                              17--19    100   --    --    --    --    --   --   --
  Vertebrae anomalies                33/33                                                          100                                                      7                                                                                              19        100   --    --    --    --    --   --   --
  **Cardiovascular defects**         19/19                                                          100                                                      81                                                                                             49--83    100   --    --    --    --    --   --   --
  **Cardiac defects**                18/19                                                          95                                                       --                                                                                             --        100   100   100   85    --    --   --   --
  Ventricular septum defect          18/19                                                          95                                                       69                                                                                             30--36    100   100   100   85    --    --   --   --
  Atrioventricular septum defect     3/12                                                           25                                                       3                                                                                              --        --    --    --    --    --    --   --   --
  **Aortic arch defects**            14/19                                                          74                                                       63                                                                                             --        100   100   90    √     100   38   42   11
  Interrupted aortic arch            14/19                                                          74                                                       23                                                                                             14--15    87    --    --    --    20    3    --   0
  Right descending aorta             5/19                                                           26                                                       43                                                                                             --        13    --    --    --    --    --   --   --

Data are derived from this study.

Data are derived from [@bib3], who examined 35 patients with DGS (43 with respect to some findings), and [@bib13], who summarized data from multiple sources. Note the high degree of variation among patients with DGS.

Data are derived from [@bib11], [@bib39], [@bib45], and [@bib49]. *Tbx1* mRNA ranges from 0% in the *Tbx1*^−/−^ to 70% of wild type in the *Tbx1*^+/Neo2^. √ indicates that defect is present but penetrance not stated. -- indicates t hat no data are available.
